Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Accumulated Expenses (2023 - 2025)

Historic Accumulated Expenses for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $4.1 million.

  • Contineum Therapeutics' Accumulated Expenses rose 789.89% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.1 million, marking a year-over-year increase of 789.89%. This contributed to the annual value of $6.7 million for FY2024, which is 5304.45% up from last year.
  • Latest data reveals that Contineum Therapeutics reported Accumulated Expenses of $4.1 million as of Q3 2025, which was up 789.89% from $3.7 million recorded in Q2 2025.
  • Contineum Therapeutics' Accumulated Expenses' 5-year high stood at $6.7 million during Q4 2024, with a 5-year trough of $2.5 million in Q2 2024.
  • Over the past 3 years, Contineum Therapeutics' median Accumulated Expenses value was $4.0 million (recorded in 2025), while the average stood at $4.3 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first soared by 5304.45% in 2024, then plummeted by 2583.82% in 2025.
  • Over the past 3 years, Contineum Therapeutics' Accumulated Expenses (Quarter) stood at $4.4 million in 2023, then surged by 53.04% to $6.7 million in 2024, then plummeted by 38.94% to $4.1 million in 2025.
  • Its Accumulated Expenses stands at $4.1 million for Q3 2025, versus $3.7 million for Q2 2025 and $3.8 million for Q1 2025.